## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

- (Currently amended) A method of inhibiting cytotoxic response of a T
  lymphocyte in a mammalian subject, said method comprising:
- a) determining said mammalian subject has a condition characterized by associated with abnormal generation or function of elevated CTL activity by assaying said activity; and
- b) administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof that binds PSGL.
  - 2-25. (Canceled)
- 26. (Previously presented) The method of claim 1, wherein said antibody is chosen from a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, and a humanized antibody, or fragments thereof that bind PSGL.
- 27. (Previously presented) The method of claim 1, wherein said antibody is administered in a pharmaceutically acceptable formulation.
- 28. (Currently amended) A method for treating or ameliorating a disease or condition resulting from a cytotoxic response of a T lymphocyte comprising:
- a) determining said mammalian subject has a condition characterized by associated with abnormal generation or function of elevated CTL activity by assaying said activity; and

- <u>b)</u> administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof that binds PSGL.
- 29. (Previously presented) The method of claim 28, wherein said disease or condition is an autoimmune condition.
- 30. (Withdrawn) The method of claim 28, wherein said disease or condition is an allergic reaction.
- 31. (Withdrawn) The method of claim 28, wherein said disease or condition is asthma.
- 32. (Previously presented) The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof that binds PSGL.
  - 33. (Canceled)
- 34. (Previously presented) The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.
  - 35. (Canceled)
- 36. (New) The method of claim 1, wherein said CTL activity is assayed in peritoneal exudate lymphocytes.
- 37. (New) The method of claim 28, wherein said CTL activity is assayed in peritoneal exudate lymphocytes.